Security
Zymeworks Inc. Common Stock · ZYME
ZYMENASDAQCommon stockCurrentCIK 1937653Updated Oct 27, 2026
Name history
Zymeworks Delaware Inc. · through Oct 13, 2022
ZYME price & chart
Loading TradingView…
NASDAQ:ZYME on TradingView ↗About the company
Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. Zymeworks’ asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.
In the news
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition ↗
Zymeworks Completes Acquisition of Theravance Biopharma ↗
Zymeworks Announces Participation in Upcoming Investor Conferences ↗
Seeking Alpha
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates - Slideshow ↗
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript ↗
Zymeworks early-stage results on ADC show anti-tumor activity in ovarian cancer ↗
Recent filings
ARS filing
DEFA14A filing
DEF 14A filing
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
PRE 14A filing
Show 5 more recent filings
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Regulation FD Disclosure
Items 1.01, 2.01, 2.03, 7.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 397,269,000Source | 487,152,000Source | 396,964,000Source | 408,385,000Source | 515,634,000Source | 478,215,000Source | 425,522,000Source | 553,752,000Source | 346,527,000Source | 463,091,000Source | 580,880,000Source | 648,725,000Source |
| Property, Plant and Equipment, NetUSD | 15,819,000Source | 18,333,000Source | 13,955,000Source | 16,314,000Source | 18,470,000Source | 14,854,000Source | 16,685,000Source | 18,972,000Source | 15,502,000Source | 17,650,000Source | 19,847,000Source | 24,713,000Source |
| GoodwillUSD | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 64,834,000Source | 122,356,000Source | 179,413,000Source | 98,253,000Source | 70,963,000Source | 244,282,000Source | 76,204,000Source | 114,814,000Source | 41,157,000Source | 66,103,000Source | 157,557,000Source | 400,912,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 29,352,000Source | 23,704,000Source | 5,930,000Source | 2,631,000Source | 32,081,000Source | 4,674,000Source | 24,594,000Source | 30,949,000Source | 4,638,000Source | 55,815,000Source | 19,477,000Source | 33,400,000Source |
| Assets, CurrentUSD | 291,712,000Source | 343,769,000Source | 298,388,000Source | 296,130,000Source | 383,495,000Source | 385,680,000Source | 306,467,000Source | 393,820,000Source | 248,767,000Source | 300,451,000Source | 412,926,000Source | 544,706,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 10,427,000Source | 22,865,000Source | 21,759,000Source | 12,120,000Source | 21,268,000Source | 16,279,000Source | 16,586,000Source | 17,824,000Source | 15,332,000Source | 18,860,000Source | 19,122,000Source | 19,074,000Source |
| Operating Lease, Right-of-Use AssetUSD | 16,648,000Source | 17,355,000Source | 13,195,000Source | 16,260,000Source | 17,279,000Source | 14,016,000Source | 16,723,000Source | 17,067,000Source | 15,724,000Source | 16,666,000Source | 17,696,000Source | 22,937,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 77,205,000Source | 120,174,000Source | 316,595,000Source | 73,879,000Source | 109,473,000Source | 314,626,000Source | 100,555,000Source | 115,753,000Source | 78,026,000Source | 124,323,000Source | 116,074,000Source | 155,769,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 1,092,929,000Source | 1,014,327,000Source | 1,133,959,000Source | 1,074,079,000Source | 1,005,310,000Source | 1,128,553,000Source | 1,021,950,000Source | 1,003,481,000Source | 1,105,176,000Source | 1,015,618,000Source | 997,227,000Source | 886,322,000Source |
| Retained Earnings (Accumulated Deficit)USD | -886,472,000Source | -797,834,000Source | -1,171,238,000Source | -850,654,000Source | -746,776,000Source | -1,073,834,000Source | -852,971,000Source | -709,090,000Source | -953,160,000Source | -830,335,000Source | -677,437,000Source | -558,763,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -6,050,000Source | -5,999,000Source | -6,694,000Source | -6,340,000Source | -7,904,000Source | -6,565,000Source | -6,406,000Source | -7,724,000Source | -6,079,000Source | -6,952,000Source | -6,603,000Source | -6,659,000Source |
| Stockholders' Equity Attributable to ParentUSD | 320,064,000Source | 366,978,000Source | 80,369,000Source | 334,506,000Source | 406,161,000Source | 163,589,000Source | 324,967,000Source | 437,999,000Source | 268,501,000Source | 338,768,000Source | 464,806,000Source | 492,956,000Source |
| Additional Paid in Capital, Common StockUSD | 111,489,000Source | 148,296,000Source | 116,450,000Source | 109,243,000Source | 147,343,000Source | 107,530,000Source | 154,216,000Source | 143,144,000Source | 114,626,000Source | 152,249,000Source | 142,274,000Source | 151,614,000Source |
| Liabilities and EquityUSD | 397,269,000Source | 487,152,000Source | 396,964,000Source | 408,385,000Source | 515,634,000Source | 478,215,000Source | 425,522,000Source | 553,752,000Source | 346,527,000Source | 463,091,000Source | 580,880,000Source | 648,725,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 42,043,000Source | 83,909,000Source | 47,243,000Source | 38,502,000Source | 54,713,000Source | 35,649,000Source | 65,103,000Source | 56,890,000Source | 42,318,000Source | 88,294,000Source | 55,763,000Source | 95,625,000Source |
| Operating Lease, Liability, CurrentUSD | 3,400,000Source | 2,943,000Source | 3,304,000Source | 3,586,000Source | 2,839,000Source | 3,279,000Source | 3,258,000Source | 4,155,000Source | 3,471,000Source | 2,740,000Source | 4,261,000Source | 3,322,000Source |
| Operating Lease, Liability, NoncurrentUSD | 15,504,000Source | 17,274,000Source | 12,703,000Source | 15,092,000Source | 17,192,000Source | 13,763,000Source | 15,174,000Source | 20,977,000Source | 14,796,000Source | 15,738,000Source | 22,369,000Source | 24,667,000Source |
| Deferred Income Tax Liabilities, NetUSD | 4,773,000Source | 3,455,000Source | 3,740,000Source | 4,850,000Source | 3,398,000Source | 3,827,000Source | 4,815,000Source | 3,351,000Source | 6,028,000Source | 4,761,000Source | 3,300,000Source | 1,788,000Source |
| Other Liabilities, NoncurrentUSD | 278,000Source | 929,000Source | 278,000Source | 828,000Source | 1,229,000Source | 278,000Source | 856,000Source | 1,594,000Source | 278,000Source | 923,000Source | 1,701,000Source | 3,101,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 1,321,000Source | 376,000Source | — | 443,000Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 216,770,000Source | 91,320,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -118,674,000Source | 124,341,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 6,935,000Source | 6,402,000Source | 28,034,000Source | 17,792,000Source | 8,102,000Source | 4,015,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 36,000Source | -31,219,000Source | -51,200,000Source | 36,359,000Source | -13,922,000Source | 17,509,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 945,000Source | 691,000Source | -757,000Source | 1,940,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -45,718,000Source | -3,407,000Source | -33,005,000Source | -110,044,000Source | -118,303,000Source | 144,109,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 69,959,000Source | 12,182,000Source | 26,663,000Source | 38,756,000Source | -207,253,000Source | -53,849,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 216,000Source | 16,000Source | 1,521,000Source | 1,991,000Source | 2,474,000Source | 8,150,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 76,151,000Source | 0Source | 41,695,000Source | 30,051,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 178,786,000Source | 1,316,000Source | -18,559,000Source | -20,452,000Source | 81,847,000Source | 108,582,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 203,125,000Source | 10,101,000Source | -24,946,000Source | -91,454,000Source | -243,355,000Source | 199,045,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 64,834,000Source | 122,356,000Source | 179,413,000Source | 98,253,000Source | 244,282,000Source | 76,204,000Source | 41,157,000Source | 66,103,000Source | 157,557,000Source | 400,912,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 245,000Source | 387,000Source | 1,350,000Source | 3,179,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 98,000Source | 10,000Source | -45,000Source | 286,000Source | 354,000Source | 203,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 176,000Source | 1,617,000Source | 4,056,000Source | 4,496,000Source | 2,702,000Source | 1,015,000Source |
| DepreciationUSD | — | — | — | — | — | — | 963,000Source | 981,000Source | 3,669,000Source | 4,188,000Source | 7,462,000Source | 6,220,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 289,000Source | -167,000Source | — | -613,000Source | — | -2,000Source | -610,000Source | 776,000Source | -1,185,000Source | 1,152,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | 331,000Source | 32,000Source | -532,000Source | 1,481,000Source | 31,000Source | 1,956,000Source |
| General and Administrative ExpenseUSD | — | — | 14,146,000Source | 13,852,000Source | 19,335,000Source | 14,951,000Source | 15,069,000Source | 16,985,000Source | 61,514,000Source | 61,506,000Source | 70,446,000Source | 73,358,000Source |
| GoodwillUSD | — | — | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source | 12,016,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 1,336,000Source | 226,000Source | -273,000Source | -186,000Source | -2,191,000Source | 496,000Source | 1,376,000Source | 6,084,000Source | -568,000Source | 10,893,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -19,602,000Source | -29,850,000Source | -45,019,000Source | 2,317,000Source | -44,162,000Source | -22,636,000Source | -81,130,000Source | -122,695,000Source | -118,674,000Source | 124,341,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -19,602,000Source | -29,850,000Source | -45,019,000Source | 2,317,000Source | -44,162,000Source | -22,636,000Source | -81,130,000Source | -122,695,000Source | -118,674,000Source | 124,341,000Source |
| Nonoperating Income (Expense)USD | — | — | 315,000Source | -204,000Source | 196,000Source | -621,000Source | 120,000Source | 49,000Source | -559,000Source | 558,000Source | -894,000Source | 1,110,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 7,795,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | 316,000Source | 0Source | 0Source | 0Source |
| Other Nonoperating Income (Expense)USD | — | — | 26,000Source | -37,000Source | — | -8,000Source | — | 51,000Source | 51,000Source | -218,000Source | 291,000Source | -42,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 3,844,000Source | 4,581,000Source | -3,112,000Source | 2,805,000Source | 765,000Source | 3,473,000Source | 12,795,000Source | 20,499,000Source | 18,811,000Source | 4,706,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 26,233,000Source | 107,534,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 8,717,000Source | 772,000Source | 16,904,000Source | 8,857,000Source | 5,006,000Source | 255,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | -667,000Source | 0Source |
| Amortization of Debt Issuance Costs | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Payments of Financing Costs | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 27,614,000Source | 16,000,000Source | 4,590,000Source | 48,726,000Source | 2,408,000Source | 27,110,000Source | 105,965,000Source | 76,304,000Source | 76,012,000Source | 412,482,000Source |
| Operating Income (Loss)USD | — | — | -22,110,000Source | -34,205,000Source | -42,180,000Source | -674,000Source | -47,118,000Source | -25,613,000Source | -92,549,000Source | -137,110,000Source | -138,053,000Source | 130,528,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 26,000Source | -37,000Source | — | -8,000Source | — | 51,000Source | 51,000Source | -218,000Source | 291,000Source | -42,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -18,266,000Source | -29,624,000Source | -45,292,000Source | 2,131,000Source | -46,353,000Source | -22,140,000Source | -79,754,000Source | -116,611,000Source | -119,242,000Source | 135,234,000Source |
| Income Tax Expense (Benefit)USD | — | — | 1,336,000Source | 226,000Source | -273,000Source | -186,000Source | -2,191,000Source | 496,000Source | 1,376,000Source | 6,084,000Source | -568,000Source | 10,893,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -19,602,000Source | -29,850,000Source | -45,019,000Source | 2,317,000Source | -44,162,000Source | -22,636,000Source | -81,130,000Source | -122,695,000Source | -118,674,000Source | 124,341,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.26Source | -0.39Source | -0.62Source | 0.03Source | -0.59Source | -0.3Source | -1.08Source | -1.62Source | -1.72Source | 1.91Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.26Source | -0.39Source | -0.62Source | 0.03Source | -0.59Source | -0.3Source | -1.08Source | -1.62Source | -1.72Source | 1.9Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 75,767,778Source | 76,128,531Source | 72,993,313Source | 75,337,168Source | 74,668,790Source | 75,171,020Source | 75,404,897Source | 75,846,681Source | 68,863,010Source | 65,194,775Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 75,775,214Source | 76,157,101Source | 72,993,313Source | 77,378,449Source | 74,694,762Source | 75,226,387Source | 75,413,396Source | 75,878,738Source | 68,863,010Source | 65,249,184Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 176,000Source | 1,617,000Source | 4,056,000Source | 4,496,000Source | 2,702,000Source | 1,015,000Source |
| Costs and ExpensesUSD | — | — | 49,724,000Source | 50,205,000Source | 46,770,000Source | 49,400,000Source | 49,526,000Source | 52,723,000Source | 198,514,000Source | 213,414,000Source | 214,065,000Source | 281,954,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 431,000Source | 5,393,000Source | 189,000Source | 8,953,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 289,000Source | -167,000Source | — | -613,000Source | — | -2,000Source | -610,000Source | 776,000Source | -1,185,000Source | 1,152,000Source |
| General and Administrative ExpenseUSD | — | — | 14,146,000Source | 13,852,000Source | 19,335,000Source | 14,951,000Source | 15,069,000Source | 16,985,000Source | 61,514,000Source | 61,506,000Source | 70,446,000Source | 73,358,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -16,809,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 3,529,000Source | 4,785,000Source | 3,287,000Source | 3,426,000Source | 2,711,000Source | 3,424,000Source | 13,354,000Source | 19,941,000Source | 19,705,000Source | 3,596,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -19,602,000Source | -29,850,000Source | -45,019,000Source | 2,317,000Source | -44,162,000Source | -22,636,000Source | -81,130,000Source | -122,695,000Source | -118,674,000Source | 124,341,000Source |
| Nonoperating Income (Expense)USD | — | — | 315,000Source | -204,000Source | 196,000Source | -621,000Source | 120,000Source | 49,000Source | -559,000Source | 558,000Source | -894,000Source | 1,110,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 7,795,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 3,844,000Source | 4,581,000Source | -3,112,000Source | 2,805,000Source | 765,000Source | 3,473,000Source | 12,795,000Source | 20,499,000Source | 18,811,000Source | 4,706,000Source |
| Research and Development ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 143,619,000Source | 208,596,000Source |
Filing attachments
d270232dex991.htm · 8-K · 2026-09-23
Exhibit 99.1 Zymeworks Completes Acquisition of Theravance Biopharma Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) ───────────────────────────────────────────────────────────────────────────────────── Vancouver, British Columbia (September 23, 2026) - Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today complete…
Read attachment ↗d156494dex991.htm · 8-K · 2026-06-29
EX-99.1 4 d156494dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Zymeworks to Acquire Theravance Biopharma, Inc. Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks’ portfolio Acquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing structure that enhances shareholder value by minimizing Zymeworks’ net capital at risk Trans…
Read attachment ↗d156494dex992.htm · 8-K · 2026-06-29
EX-99.2 5 d156494dex992.htm EX-99.2 EX-99.2 Nasdaq: ZYME | zymeworks.com Agreement to Acquire Theravance Biopharma June 29, 2026 Transaction delivers high-visibility, long-duration recurring cash flows Exhibit 99.2 This presentation includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-lookin…
Read attachment ↗d110930dex991.htm · 8-K · 2026-05-14
EX-99.1 2 d110930dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock Vancouver, British Columbia (May 14, 2026) - Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a 2026 share repurchase program under which the Company may …
Read attachment ↗d142598dex991.htm · 8-K · 2026-04-01
EX-99.1 3 d142598dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Zymeworks Appoints Kristin Stafford as Chief Financial Officer Vancouver, British Columbia (April 1, 2026) - Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin Stafford as Chief Financial Officer, effective April 1, 2026. “Kristin brings deep experience…
Read attachment ↗d97670dex991.htm · 8-K · 2026-01-12
Exhibit 99.1 Zymeworks Outlines Strategic Priorities and Outlook for 2026 Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and China Company well-positioned to execute new strategy compounding long-term value by inte…
Read attachment ↗